Today's Research on Celsion, Zogenix, Actavis, and Avanir Pharma

Wed Apr 10, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130410:nPn4109468


LONDON,  April 10, 2013  /PRNewswire/ --

One of the major trends to emerge in the healthcare industry in the last year
has been the expiration of patents on several blockbuster drugs. This had led to
increasing competition from generic drug companies such as Actavis Inc. (NYSE:
ACT) and Avanir Pharmaceuticals Inc. (NASDAQ: AVNR). For major drug
manufacturers such as Zogenix Inc. (NASDAQ: ZGNX), the key will be to continue
to boost their product pipeline. Major drug manufacturers are also likely to
collaborate with biotechnology companies such as Celsion Corporation (NASDAQ:
CLSN) that are developing or have developed potential blockbuster drugs. On
Tuesday, healthcare stocks ended on a mixed note even as the broad market posted
significant gains. StockCall professionals have completed their technical
analysis on CLSN, ZGNX, ACT, and AVNR and these free reports are accessible by
registering at

http://www.stockcall.com/research   

Shares of Celsion Corporation edged higher yesterday; however, the gains were
limited. The stock touched an intra-day high of  $1  before finishing the day
0.41% higher at  $0.974  on volume of 523,658. Despite the gains on Tuesday,
Celsion's shares have fallen more than 4.50% in the last three trading sessions.
Year-to-date, the stock has lost more than 88% of its value. Most of the losses
came in February when the stock saw a steep decline. In the last one month,
shares of CLSN have traded sideways, struggling to break through  $1  level.
Sign up for the free technical research on CLSN at

http://www.StockCall.com/CLSN041013.pdf

Shares of Zogenix Inc. saw a sharp decline in trading on Tuesday. The stock
ended the day 2.52% lower at  $1.55  on volume of 515,540. The stock has now
fallen more than 13.40% in the last three trading sessions. The major drug
maker's shares have fallen sharply after the stock failed to break through  $2 
resistance level. The stock recently slipped below  $1.60  support level, and
also its 50-day moving average. This suggests that market sentiment is currently
bearish on the stock. The downbeat trend is further confirmed by the stock's
MACD chart. Be sure to read our latest technical research on ZGNX by registering
at

http://www.StockCall.com/ZGNX041013.pdf

Actavis Inc.'s shares ended marginally lower on Tuesday. The stock touched a
52-week high of  $98.46  earlier in the day; however, it failed to hold onto its
gains. Actavis' shares ended the day 0.66% lower at  $97.71  on volume of 1.10
million. Despite the losses yesterday, the generic drug maker's shares are still
up nearly 2% in the last three trading sessions. The stock has had an excellent
run so far in 2013, gaining more than 13.60%. The company's shares have seen a
series of highs since last month, which is a bullish signal. Sign up and read
the complimentary report on ACT at

http://www.StockCall.com/ACT041013.pdf

Avanir Pharmaceuticals Inc.'s shares were among the major gainers in the
healthcare sector on Tuesday. The stock closed 2.65% higher at  $2.71  on volume
of 594,199 after touching an intra-day high of  $2.77. Avanir's shares are
currently trading more than 33% below their 52-week high. The stock bounced back
yesterday after seeing a series of lows in the past two weeks. Shares of this
generic drug maker are still trading well below their 50-day and 200-day moving
averages, which is a bearish signal. The negative trend is further confirmed by
the stock's MACD chart.  The free report on AVNR can be downloaded by signing up
now at

http://www.StockCall.com/AVNR041013.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up
today to talk to our financial analyst at

http://www.stockcall.com   

SOURCE  StockCall.com


Contact Person: William T. Knight, Email: info@stockcall.com, Contact Number:
+1(646)396-9857 (9:00 am EST - 01:30 pm EST)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.